Exemestane profile
Exemestane for Sale
Clinical trials have shown that the metastatic breast cancer exemestane more pronounced compared to tamoxifen, slow disease progression, but does not affect the process of metastasis. Randomized MA-17, Research ATAS, IES showed that it differs from the spectrum of toxicity of non-steroidal aromatase inhibitor, but the therapeutic value of this data has not been studied. The drug is subjectively very well tolerated; the most common side effects are hot flushes (19%) and nausea (21%). According to the severity of impact on the development of osteoporosis and the incidence of pathological fractures in patients treated with exemestane, letrozole is not inferior. The risk of pathological fractures compared with the control group (placebo) for exemestane is increased by 60%! Arthralgia accompany the drug in 4.5% of cases, which is higher than that of tamoxifen (3.6%). However, the risk of endometrial cancer, as well as arterial and venous thrombosis significantly lower for exemestane (and also letrozole) than tamoxifen. The frequency of appearance of dryness and itching of the urogenital region when receiving exemestane above, and vaginal discharge – lower than tamoxifen.
Action exemestane on mental ability tests in the above MA-17, ATAS, the IES has not been studied. However, all taking anti-estrogen drugs, you should think about the fact that a lack of endogenous estrogen, even against the background replacement therapy significantly increases the risk of developing dementia in the future.
This product is available in the following variations:
- Exedrol by Balkan Pharmaceuticals